Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates YJ Yu, JK Atwal, Y Zhang, RK Tong, KR Wildsmith, C Tan, N Bien-Ly, ... Science translational medicine 6 (261), 261ra154-261ra154, 2014 | 376 | 2014 |
Apparatus and method for computer modeling type 1 diabetes K Gadkar, H Kreuwel, T Paterson, D Polidori, S Ramanujan, LKM Shoda, ... US Patent App. 11/377,614, 2007 | 327 | 2007 |
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier JA Couch, YJ Yu, Y Zhang, JM Tarrant, RN Fuji, WJ Meilandt, H Solanoy, ... Science translational medicine 5 (183), 183ra57-183ra57, 2013 | 265 | 2013 |
Iterative approach to model identification of biological networks KG Gadkar, R Gunawan, FJ Doyle BMC bioinformatics 6, 1-20, 2005 | 202 | 2005 |
A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions A Kremling, S Fischer, K Gadkar, FJ Doyle, T Sauter, E Bullinger, ... Genome research 14 (9), 1773-1785, 2004 | 157 | 2004 |
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3 D Slaga, D Ellerman, TN Lombana, R Vij, J Li, M Hristopoulos, R Clark, ... Science translational medicine 10 (463), eaat5775, 2018 | 123 | 2018 |
A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models B van Lengerich, L Zhan, D Xia, D Chan, D Joy, JI Park, D Tatarakis, ... Nature neuroscience 26 (3), 416-429, 2023 | 104 | 2023 |
Model identification of signal transduction networks from data using a state regulator problem KG Gadkar, J Varner, FJ Doyle III Systems Biology 2 (1), 17-30, 2005 | 102 | 2005 |
Estimating optimal profiles of genetic alterations using constraint‐based models KG Gadkar, FJ Doyle Iii, JS Edwards, R Mahadevan Biotechnology and bioengineering 89 (2), 243-251, 2005 | 98 | 2005 |
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling I Hosseini, K Gadkar, E Stefanich, CC Li, LL Sun, YW Chu, S Ramanujan NPJ systems biology and applications 6 (1), 28, 2020 | 89 | 2020 |
A six‐stage workflow for robust application of systems pharmacology K Gadkar, DC Kirouac, DE Mager, PH van der Graaf, S Ramanujan CPT: pharmacometrics & systems pharmacology 5 (5), 235-249, 2016 | 87 | 2016 |
Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics K Gadkar, CV Pastuskovas, JE Le Couter, JM Elliott, J Zhang, CV Lee, ... Investigative Ophthalmology & Visual Science 56 (9), 5390-5400, 2015 | 75 | 2015 |
On-line adaptation of neural networks for bioprocess control KG Gadkar, S Mehra, J Gomes Computers & chemical engineering 29 (5), 1047-1057, 2005 | 74 | 2005 |
Cybernetic model predictive control of a continuous bioreactor with cell recycle KG Gadkar, FJD III, TJ Crowley, JD Varner Biotechnology progress 19 (5), 1487-1497, 2003 | 74 | 2003 |
Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model LA Hutton-Smith, EA Gaffney, HM Byrne, PK Maini, K Gadkar, NA Mazer Molecular pharmaceutics 14 (8), 2690-2696, 2017 | 63 | 2017 |
Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model DC Kirouac, G Schaefer, J Chan, M Merchant, C Orr, SMA Huang, J Moffat, ... NPJ systems biology and applications 3 (1), 14, 2017 | 62 | 2017 |
The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse L Shoda, H Kreuwel, K Gadkar, Y Zheng, C Whiting, M Atkinson, ... Clinical & Experimental Immunology 161 (2), 250-267, 2010 | 55 | 2010 |
Mechanism-based pharmacokinetic/pharmacodynamic model for THIOMAB™ drug conjugates S Sukumaran, K Gadkar, C Zhang, S Bhakta, L Liu, K Xu, H Raab, SF Yu, ... Pharmaceutical research 32, 1884-1893, 2015 | 52 | 2015 |
Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain K Gadkar, DB Yadav, JY Zuchero, JA Couch, J Kanodia, MK Kenrick, ... European Journal of Pharmaceutics and Biopharmaceutics 101, 53-61, 2016 | 51 | 2016 |
A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations K Gadkar, N Budha, A Baruch, JD Davis, P Fielder, S Ramanujan CPT: pharmacometrics & systems pharmacology 3 (11), 1-9, 2014 | 49 | 2014 |